KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) EBIT: 2011-2025

Historic EBIT for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to -$60.2 million.

  • Supernus Pharmaceuticals' EBIT fell 247.46% to -$60.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$36.9 million, marking a year-over-year decrease of 162.33%. This contributed to the annual value of $81.7 million for FY2024, which is 1649.93% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported EBIT of -$60.2 million as of Q3 2025, which was down 596.10% from $12.1 million recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' EBIT peaked at $40.8 million during Q3 2024, and registered a low of -$60.2 million during Q3 2025.
  • For the 3-year period, Supernus Pharmaceuticals' EBIT averaged around $1.6 million, with its median value being $5.2 million (2023).
  • Its EBIT has fluctuated over the past 5 years, first tumbled by 255.01% in 2023, then soared by 2,249.10% in 2024.
  • Over the past 5 years, Supernus Pharmaceuticals' EBIT (Quarterly) stood at $6.1 million in 2021, then spiked by 463.04% to $34.3 million in 2022, then crashed by 102.90% to -$996,000 in 2023, then spiked by 2,249.10% to $21.4 million in 2024, then crashed by 247.46% to -$60.2 million in 2025.
  • Its last three reported values are -$60.2 million in Q3 2025, $12.1 million for Q2 2025, and -$10.3 million during Q1 2025.